Abstract
Hospitalization rates and survival of patients with Heart Failure (HF) have improved.
However, 5-year mortality rates remain high and the prevalence of the disease is rising likely due to
aging of the population and advances in diagnosis and treatment of other acute and chronic cardiovascular
diseases. Over the past three decades the therapeutic armamentarium of heart failure has improved
substantially with development of medications targeting neuro-hormonal activation and devices
preventing sudden cardiac death and improving cardiac synchrony. Recently, inhibition of angiotensin
receptors and neprilysin as well as sinoatrial pacemaker modulating f-current, have been
found safe and effective strategies that improve HF hospitalization rates and/or mortality. Antidiabetic
agents inhibiting sodium-glucose co-transporters 2, result in natriuresis and osmotic diuresis
and may further improve HF related outcomes. Furthermore, emerging therapies such as cardiac myosin
activators, soluble guanylate cyclase stimulators and non-steroidal mineralocorticoid receptor
antagonists are undergoing investigation in phase II and III studies of HF patients. Finally, rapid evolution
of in the management of advanced HF has occurred with the application of second and third
generation continuous flow left ventricular assist devices in clinical practice. Ongoing clinical studies
will validate the safety and efficacy of emerging therapeutic strategies in HF population underrepresented
in previous clinical trials.
Keywords:
Heart failure, neprylysin inhibitor, ivabradin, left ventricular assist device, novel therapy, sinoatrial
pacemaker.
[1]
Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; Das, S.R.; de Ferranti, S.; Després, J.P.; Fullerton, H.J.; Howard, V.J.; Huffman, M.D.; Isasi, C.R.; Jiménez, M.C.; Judd, S.E.; Kissela, B.M.; Lichtman, J.H.; Lisabeth, L.D.; Liu, S.; Mackey, R.H.; Magid, D.J.; McGuire, D.K.; Mohler, E.R., III; Moy, C.S.; Muntner, P.; Mussolino, M.E.; Nasir, K.; Neumar, R.W.; Nichol, G.; Palaniappan, L.; Pandey, D.K.; Reeves, M.J.; Rodriguez, C.J.; Rosamond, W.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.N.; Virani, S.S.; Woo, D.; Yeh, R.W.; Turner, M.B. American Heart Association Statistics Committee;Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American heart association.
Circulation, 2016,
133(4), e38-e360.
[
http://dx.doi.org/10.1161/CIR.0000000000000350] [PMID:
26673558]
[12]
Packer, M.; McMurray, J.J.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.; Andersen, K.; Arango, J.L.; Arnold, J.M.; Bělohlávek, J.; Böhm, M.; Boytsov, S.; Burgess, L.J.; Cabrera, W.; Calvo, C.; Chen, C.H.; Dukat, A.; Duarte, Y.C.; Erglis, A.; Fu, M.; Gomez, E.; Gonzàlez-Medina, A.; Hagège, A.A.; Huang, J.; Katova, T.; Kiatchoosakun, S.; Kim, K.S.; Kozan, Ö.; Llamas, E.B.; Martinez, F.; Merkely, B.; Mendoza, I.; Mosterd, A.; Negrusz-Kawecka, M.; Peuhkurinen, K.; Ramires, F.J.; Refsgaard, J.; Rosenthal, A.; Senni, M.; Sibulo, A.S., Jr; Silva-Cardoso, J.; Squire, I.B.; Starling, R.C.; Teerlink, J.R.; Vanhaecke, J.; Vinereanu, D.; Wong, R.C. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Circulation, 2015,
131(1), 54-61.
[
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013748] [PMID:
25403646]
[13]
McMurray, J.; Packer, M.; Desai, A.; Gong, J.; Greenlaw, N.; Lefkowitz, M.; Rizkala, A.; Shi, V.; Rouleau, J.; Solomon, S.; Swedberg, K.; Zile, M.R.; Andersen, K.; Arango, J.L.; Arnold, M.; Bĕlohlávek, J.; Böhm, M.; Boytsov, S.; Burgess, L.; Cabrera, W.; Chen, C.H.; Erglis, A.; Fu, M.; Gomez, E.; Gonzalez, A.; Hagege, A.A.; Katova, T.; Kiatchoosakun, S.; Kim, K.S.; Bayram, E.; Martinez, F.; Merkely, B.; Mendoza, I.; Mosterd, A.; Negrusz-Kawecka, M.; Peuhkurinen, K.; Ramires, F.; Refsgaard, J.; Senni, M.; Sibulo, A.S., Jr; Silva-Cardoso, J.; Squire, I.; Starling, R.C.; Vinereanu, D.; Teerlink, J.R.; Wong, R. PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Eur. Heart J., 2015,
36(7), 434-439.
[
http://dx.doi.org/10.1093/eurheartj/ehu455] [PMID:
25416329]
Download PDF Flyer